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Background
The primary objective of our current HIV vaccine research
program is to develop and evaluate novel recombinant
alphavirus replicon and Env protein-based vaccine formu-
lations against HIV that may offer improved immuno-
genicity and protective efficacy over other HIV vaccine
approaches tested. Our approach described here is to
employ diverse HIV Env antigens from transmitted HIV
strains as substrates for the development of vaccine
immunogens with enhanced exposure to the immune sys-
tem of the conserved epitopes involved in virus binding/
entry. Previously, we showed that full protection of
macaques from mucosal homologous SHIV challenge was
achieved using recombinant VEE/SIN alphavirus Env
prime Env protein boost. The aim of the present work is
to build upon this work to identify novel Env immuno-
gens.
Methods
22 early transmitted HIV-1 clade C envelopes were
selected following specific criteria. For each envelope,
gp140 uncleaved and gp140 uncleaved ΔV1V2 codon
optimized genes were cloned and expressed in plasmid
and alphavirus (VEE/SIN)-based vectors. In addition, the
corresponding gp160 gene was used to produce molecu-
larly matched infectious pseudoparticles for virus neutral-
ization studies.
Results
All envelopes showed high levels of expression in 293T
cells and 50% showed substantial levels of secretion into
the cell culture medium. For each envelope, the expressed
proteins were characterized for sCD4 and MAb binding to
establish their integrity as well as their antigenic proper-
ties. The neutralization sensitivities of corresponding
pseudoviruses are also under evaluation, and infectious
recombinant alphavirus replicon particles expressing
these Envs are in preparation.
Conclusion
We produced and characterized new vaccine candidates
for preclinical evaluations based on 22 clade C HIV enve-
lopes from early transmitted viruses. Immunizations
using alphavirus prime plus Env protein boost will be ini-
tiated to elucidate the in vivo epitope recognition of these
Env by animal hosts, and the relative abilities of these new
antigens to induce virus neutralizing responses.
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